Tweets
CARRA STOP-JIA 400pts, Obs study w/ 3 treatments plans :
-Step up
-Early combination
-Biologic first
Which one do you think works best?
I'd say none: overall 40-60% not achieving CDI off steroids at 24 months.
Results: 42% for SU, 52% EC, and 44% BF #Abtr0960 #ACR21 @RheumNow
Aurelie Najm @AurelieRheumo ( View Tweet )
4 years 8 months ago
Are these pictures representative of a Sjogren's tongue or oral candidiasis?
Comment below with your thoughts!
#ACR21 #ClinicalPearls
@RheumNow https://t.co/yGHA0pA7w0
Meral K. El Ramahi, MD @MeralElRamahiMD ( View Tweet )
4 years 8 months ago
7S125 Interesting talk on Anatomy for the Clinician: Putting Your Best Foot Forward
#ACR21 @RheumNow https://t.co/zLbDW9yfEb
Akhil Sood MD @AkhilSoodMD ( View Tweet )
4 years 8 months ago
Awesome presentation today from Dr. Cristina Ruiz-Romero on lipidomic profiles in RA vs PsA. Using mass spectrometry, found differences in both synovial bx and fluid. Potentially useful lipid markers, more studies to follow.
#ACR21 #ACRBest Abst#0946 @RheumNow https://t.co/KmWCPKijSx
Pedro Castillo @_Castillo_Pedro ( View Tweet )
4 years 8 months ago
Andy 0963 #ACR21 @RheumNow covid19 vaccine immunogenicity in rheum pts overall good at 71%, fairly dependent on Rx choice: rituximab 38% after 1g & only 7 % after 1gx2; abatacept IV 45%. Rest biologics >80%, ⬇️MTX &MMF. Low dose prednisone w/out biologics did not affect Ab+ rates https://t.co/TkCC1sgMHG
Olga Petryna @DrPetryna ( View Tweet )
4 years 8 months ago
Infx oral session
0964 Bitoun, et al.
RTX lowers neutralizing Ab response compared to healthy controls, after COVID vaccination -- more supportive data
https://t.co/6jvWHSjIgr
#ACR21
Rheum Cat @rheum_cat ( View Tweet )
4 years 8 months ago
#ultrasound led to a change in Dx or Tx 2/3 of the time in a Sports Med clinic! #ACR21 #ACRAmbassador #POCUS https://t.co/2CviSOQKiz
Arthur Mandelin, MD/PhD, RhMSUS, RMSK @NU_Rheum_MSK_US ( View Tweet )
4 years 8 months ago
Tofacitinib vs TNF inhibitors in #RA patients +50yrs with >1 CV risk factor; the data from ORAL Surveillance that we have all been waiting for! #ACR21
Risk of MACE related largely to baseline CV risk https://t.co/SpuKTtP8ql
The Lancet Rheumatology @TheLancetRheum ( View Tweet )
4 years 8 months ago
To add numbers to this - using ARR because it's easiest:
Vitamin D: 123/12,937 = 0.95% rheum dx
Placebo: 155/12,937 = 1.20% rheum dx
ARR = 0.25% or NNT of 400 to prevent 1 case of rheum dx
Better get prescribing ASAP!
Mike Putman @EBRheum ( View Tweet )
4 years 8 months ago
#ACR21 #ACRAmbassador
Fascinating analysis of rheum dx from the (negative!) VITAL study (https://t.co/aMtMCIf1F1)
Very few pts 278/25,871 (1.1%) but HR 0.78, p = 0.045 for vitamin D preventing autoimmune disease
Do you believe it? If so, what's your public policy advice? https://t.co/ZkO5nHAJz9
Mike Putman @EBRheum ( View Tweet )
4 years 8 months ago
ORAL-Surveillance, an open label Phase 3b/4 RCT of tofacitinib (JAKi) vs TNFi in RA
Numerical elevations in MACE and MI, highest among pts w/hx of CAD or high 10-year risk for MACE
I have been considering baseline CVD / VTE / CA risk when prescribing these since this broke https://t.co/8DAx8IgnZM
Mike Putman @EBRheum ( View Tweet )
4 years 8 months ago
Dr Blazer sheds light on the multilayered SDOHs as they affect outcomes in chronic diseases. Head over to #ACR21 https://t.co/Jq7aiRV3MD
Chinny Jumai Osuorji,MD @MediaRheum ( View Tweet )
4 years 8 months ago
